Document is current

Article History

Received: 6 October 2020

Revised: 14 January 2021

Accepted: 28 January 2021

First Online: 25 March 2021

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: P.-M.M. was supported by the Cancer Institut Thématique Multi-Organisme of the French National Alliance for Life and Health Sciences (AVIESAN) Plan Cancer 2014-2019 (doctoral grant) and from the Comprehensive Cancer Center F. Baclesse. P.-M.M., L.-B.W., B.L. and L.P. are members of the “Réseau Normand d’Innovation Thérapeutique en Oncologie (ONCOTHERA)” network. “ONCOTHERA” European project is co-funded by the Normandy County Council and the European Union within the framework of the Operational Program ERDF/ESF 2014-2020. Work of the laboratory on ovarian cancer organoids is supported by Cancéropôle Nord-Ouest (“ORGRAFT” project), Ligue contre le Cancer (Calvados’s commitee), Fondation de l’Avenir (#AP-RM-19-020), the “Fondation ARC pour la recherche sur le cancer” (#PJA20191209649), and by the Normandy County Council and the European Union within the framework of the Operational Program ERDF/ESF 2014-2020 (“ORGATHEREX” and “ORGAPRED” projects).

: None.